Equities analysts predict that Alkermes Plc (NASDAQ:ALKS) will post sales of $221.82 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Alkermes’ earnings. The highest sales estimate is $228.70 million and the lowest is $214.94 million. Alkermes posted sales of $191.78 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 15.7%. The firm is expected to issue its next earnings report on Thursday, April 26th.
According to Zacks, analysts expect that Alkermes will report full-year sales of $221.82 million for the current financial year, with estimates ranging from $987.90 million to $1.02 billion. For the next year, analysts forecast that the firm will report sales of $1.15 billion per share, with estimates ranging from $990.20 million to $1.24 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Alkermes.
Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Wednesday, February 14th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.32. The business had revenue of $275.37 million for the quarter, compared to analysts’ expectations of $251.23 million. Alkermes had a negative return on equity of 4.32% and a negative net margin of 17.48%. The business’s quarterly revenue was up 29.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.02 EPS.
Shares of Alkermes (ALKS) opened at $60.53 on Tuesday. The company has a current ratio of 2.78, a quick ratio of 2.46 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $9,310.00, a P/E ratio of -64.39 and a beta of 1.87. Alkermes has a 1 year low of $46.42 and a 1 year high of $71.22.
In other news, Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $57.04, for a total transaction of $57,040.00. Following the completion of the sale, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $513,360. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Laurie Keating sold 6,249 shares of the firm’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 125,433 shares of company stock valued at $7,942,327. 5.34% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ALKS. SG Americas Securities LLC bought a new stake in shares of Alkermes during the 4th quarter worth $114,000. Quantbot Technologies LP bought a new stake in shares of Alkermes during the 3rd quarter worth $126,000. Virtu Financial LLC bought a new stake in shares of Alkermes during the 3rd quarter worth $201,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Alkermes during the 3rd quarter worth $214,000. Finally, Trexquant Investment LP bought a new stake in shares of Alkermes during the 3rd quarter worth $218,000.
ILLEGAL ACTIVITY NOTICE: “$221.82 Million in Sales Expected for Alkermes Plc (ALKS) This Quarter” was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/03/13/221-82-million-in-sales-expected-for-alkermes-plc-alks-this-quarter.html.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.